What this means
This is a plan for a study that will check if an IV stem cell treatment is safe for frail older adults. It has not started recruiting, and no results have been posted yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 60–85
- Where
- Not listed
The science
- Registered title
- Safety Study of Intravenous MiraMSC in Older Adults With Mild to Moderate Frailty Syndrome
- Trial ID
- NCT07705464 ↗
- Phase
- PHASE 1
- Study type
- interventional
- Conditions
- Frailty
- What is tested
- MiraMSC-FS-001
- Sponsor
- Miracle Biomedical Co., Ltd.
- Ages
- 60 Years to 85 Years
- Dates
- First posted Jul 15, 2026 · updated Jul 15, 2026
Registry summary
The purpose of this Phase I, open-label study is to evaluate the safety and tolerability of intravenous MiraMSC-FS-001 in older adults with mild to moderate frailty syndrome. MiraMSC-FS-001 is an investigational product consisting of allogeneic umbilical cord-derived mesenchymal stem cells (UCMSCs). Eligible participants will receive intravenous administration of MiraMSC-FS-001.